申请人:Hoffmann-La Roche Inc.
公开号:US10093657B2
公开(公告)日:2018-10-09
This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.
本申请公开了根据通式(I):其中所有变量的定义如本文所述,可抑制 Btk 的化合物。本文公开的化合物可用于调节 Btk 的活性,治疗与 Btk 活性过高有关的疾病。这些化合物可用于治疗由异常 B 细胞活化引起的肿瘤、自身免疫和炎症性疾病。还公开了含有式(I)化合物和至少一种载体、稀释剂或赋形剂的组合物。